Literature DB >> 34152842

Acute Pain Crisis Caused by Tramadol Remdesivir Drug-Drug Interaction.

Dac Teoli1, Virginia Thompson2, Jessica Wright2, Ivana Ho3, Brittany Vlaminck3, Gina Miller3, Molly Feely1.   

Abstract

Drug interactions are common and can affect patient outcomes. Drugs that undergo emergency approval have less preapproval drug testing to identify potential interactions. Tramadol is an effective pain medication prodrug with a complex mechanism of action that requires extensive metabolism. Remdesivir is an antiviral medication given emergency approval to treat hospitalized patients with COVID-19 infections. Remdesivir is also a nucleotide analogue prodrug that undergoes intracellular metabolic conversions to its active metabolite. We discuss the case of a hospitalized patient in the United States diagnosed with COVID-19 pneumonia who developed acute pain crisis secondary to a drug-drug interaction between tramadol and remdesivir, and we propose a possible mechanism of interaction.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; pain crisis; palliative care; remdesivir; tramadol

Year:  2021        PMID: 34152842     DOI: 10.1089/jpm.2021.0123

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  2 in total

1.  Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review.

Authors:  Valeria Conti; Carmine Sellitto; Martina Torsiello; Valentina Manzo; Emanuela De Bellis; Berenice Stefanelli; Nicola Bertini; Maria Costantino; Chiara Maci; Emanuel Raschi; Francesco Sabbatino; Graziamaria Corbi; Pasquale Pagliano; Amelia Filippelli
Journal:  JAMA Netw Open       Date:  2022-04-01

Review 2.  The Pharmacist's Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications.

Authors:  Mohammed Salim Karattuthodi; Shabeer Ali Thorakkattil; Suhaj Abdulsalim; Sathvik Belagodu Sridhar; Sainul Abideen Parakkal; Savera Arain; Hafees Madathil; Ajmal Karumbaru Kuzhiyil; Mamdouh Mohammed Ahmed Ageeli; Mazhuvanchery Kesavan Unnikrishnan
Journal:  Pharmacy (Basel)       Date:  2022-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.